Personalized medicine: The road ahead

Rutika Mehta, Rohit Jain, Sunil Badve

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

With breast cancer now being recognized as a heterogeneous disease, the concept of personalized medicine demands that the tumor of every individual be treated uniquely. This has lead to ever-expanding use of existing prognostic and predictive markers, and the search for better ones is ongoing. The classic prognostic tools such as tumor size, lymph node status, grade, hormone receptors, and HER2 status are now supplemented by gene expression-based tools such as PAM50 and MammaPrint. However, the overdependence of these tools on proliferation-related genes is a significant handicap. Although pathway-based signatures hold great promise in future breast cancer prognostication, the fact that every tumor has multiple functional pathways significantly limits the utility of this approach. Developed by the integration of estrogen receptor (ER), HER2, proliferation-related, and other genes, the Oncotype DX assay has been able to provide valuable prognostic information for ER-positive tumors. Newer molecular markers based on cancer stem cells, single-nucleotide polymorphisms (SNPs), and miRNAs are becoming available, but their importance needs to be validated. It is clear that breast cancer is a multifaceted process and that none of the tools can reliably predict a binary outcome (recurrence or no recurrence). The breast cancer community is still awaiting an ideal prognostic tool that can integrate knowledge from classic variables such as tumor size and grade with new throughput technology and principles of pharmacogenomics. Such a tool will not only define prognostic subgroups but also be able to predict therapeutic efficacy and/or resistance based on molecular profiling.

Original languageEnglish
Pages (from-to)20-26
Number of pages7
JournalClinical Breast Cancer
Volume11
Issue number1
DOIs
StatePublished - Mar 1 2011

Fingerprint

Precision Medicine
Breast Neoplasms
Neoplasms
Estrogen Receptors
Recurrence
Neoplastic Stem Cells
Pharmacogenetics
MicroRNAs
Genes
Single Nucleotide Polymorphism
Lymph Nodes
Hormones
Technology
Gene Expression

Keywords

  • Future directions
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Personalized medicine : The road ahead. / Mehta, Rutika; Jain, Rohit; Badve, Sunil.

In: Clinical Breast Cancer, Vol. 11, No. 1, 01.03.2011, p. 20-26.

Research output: Contribution to journalArticle

Mehta, Rutika ; Jain, Rohit ; Badve, Sunil. / Personalized medicine : The road ahead. In: Clinical Breast Cancer. 2011 ; Vol. 11, No. 1. pp. 20-26.
@article{96f18938298a4a2b9f24974e40517caf,
title = "Personalized medicine: The road ahead",
abstract = "With breast cancer now being recognized as a heterogeneous disease, the concept of personalized medicine demands that the tumor of every individual be treated uniquely. This has lead to ever-expanding use of existing prognostic and predictive markers, and the search for better ones is ongoing. The classic prognostic tools such as tumor size, lymph node status, grade, hormone receptors, and HER2 status are now supplemented by gene expression-based tools such as PAM50 and MammaPrint. However, the overdependence of these tools on proliferation-related genes is a significant handicap. Although pathway-based signatures hold great promise in future breast cancer prognostication, the fact that every tumor has multiple functional pathways significantly limits the utility of this approach. Developed by the integration of estrogen receptor (ER), HER2, proliferation-related, and other genes, the Oncotype DX assay has been able to provide valuable prognostic information for ER-positive tumors. Newer molecular markers based on cancer stem cells, single-nucleotide polymorphisms (SNPs), and miRNAs are becoming available, but their importance needs to be validated. It is clear that breast cancer is a multifaceted process and that none of the tools can reliably predict a binary outcome (recurrence or no recurrence). The breast cancer community is still awaiting an ideal prognostic tool that can integrate knowledge from classic variables such as tumor size and grade with new throughput technology and principles of pharmacogenomics. Such a tool will not only define prognostic subgroups but also be able to predict therapeutic efficacy and/or resistance based on molecular profiling.",
keywords = "Future directions, Prognostic factors",
author = "Rutika Mehta and Rohit Jain and Sunil Badve",
year = "2011",
month = "3",
day = "1",
doi = "10.3816/CBC.2011.n.004",
language = "English",
volume = "11",
pages = "20--26",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Personalized medicine

T2 - The road ahead

AU - Mehta, Rutika

AU - Jain, Rohit

AU - Badve, Sunil

PY - 2011/3/1

Y1 - 2011/3/1

N2 - With breast cancer now being recognized as a heterogeneous disease, the concept of personalized medicine demands that the tumor of every individual be treated uniquely. This has lead to ever-expanding use of existing prognostic and predictive markers, and the search for better ones is ongoing. The classic prognostic tools such as tumor size, lymph node status, grade, hormone receptors, and HER2 status are now supplemented by gene expression-based tools such as PAM50 and MammaPrint. However, the overdependence of these tools on proliferation-related genes is a significant handicap. Although pathway-based signatures hold great promise in future breast cancer prognostication, the fact that every tumor has multiple functional pathways significantly limits the utility of this approach. Developed by the integration of estrogen receptor (ER), HER2, proliferation-related, and other genes, the Oncotype DX assay has been able to provide valuable prognostic information for ER-positive tumors. Newer molecular markers based on cancer stem cells, single-nucleotide polymorphisms (SNPs), and miRNAs are becoming available, but their importance needs to be validated. It is clear that breast cancer is a multifaceted process and that none of the tools can reliably predict a binary outcome (recurrence or no recurrence). The breast cancer community is still awaiting an ideal prognostic tool that can integrate knowledge from classic variables such as tumor size and grade with new throughput technology and principles of pharmacogenomics. Such a tool will not only define prognostic subgroups but also be able to predict therapeutic efficacy and/or resistance based on molecular profiling.

AB - With breast cancer now being recognized as a heterogeneous disease, the concept of personalized medicine demands that the tumor of every individual be treated uniquely. This has lead to ever-expanding use of existing prognostic and predictive markers, and the search for better ones is ongoing. The classic prognostic tools such as tumor size, lymph node status, grade, hormone receptors, and HER2 status are now supplemented by gene expression-based tools such as PAM50 and MammaPrint. However, the overdependence of these tools on proliferation-related genes is a significant handicap. Although pathway-based signatures hold great promise in future breast cancer prognostication, the fact that every tumor has multiple functional pathways significantly limits the utility of this approach. Developed by the integration of estrogen receptor (ER), HER2, proliferation-related, and other genes, the Oncotype DX assay has been able to provide valuable prognostic information for ER-positive tumors. Newer molecular markers based on cancer stem cells, single-nucleotide polymorphisms (SNPs), and miRNAs are becoming available, but their importance needs to be validated. It is clear that breast cancer is a multifaceted process and that none of the tools can reliably predict a binary outcome (recurrence or no recurrence). The breast cancer community is still awaiting an ideal prognostic tool that can integrate knowledge from classic variables such as tumor size and grade with new throughput technology and principles of pharmacogenomics. Such a tool will not only define prognostic subgroups but also be able to predict therapeutic efficacy and/or resistance based on molecular profiling.

KW - Future directions

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=79953792732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953792732&partnerID=8YFLogxK

U2 - 10.3816/CBC.2011.n.004

DO - 10.3816/CBC.2011.n.004

M3 - Article

C2 - 21421518

AN - SCOPUS:79953792732

VL - 11

SP - 20

EP - 26

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -